Stephen Cutler is a natural products chemist whose research interests are focused on the isolation, biological evaluation and structural elucidation of bioactive secondary metabolites from nature, including the accession of fungi and plant that have unique properties. In addition, his work includes the design and synthesis of derivatives of the metabolites as ligands to serve as probes to investigate pharmacologic receptors. For 10 years Stephen served as the principal investigator of an NIH-COBRE center grant. Main objectives of his research are to develop new approaches and concepts to designing highly selective ligands. Most of his recent research activities have involved the isolation and structural elucidation of biologically active natural products that are selective for the cannabinoid and opioid receptor types. These studies have utilized both cloned receptors (developed in his laboratory) and animal studies as an aid to obtain insight into the recognition of ligands by these CNS and peripheral receptors.
During his career, Dr. Cutler has received more than $35,000,000 from various federal agencies including the NIH, NSF, DoD, CDC, NASA, and the USDA. He is the author or co-author of more than 45 patents (US and international), 120 peer-reviewed publications, 3 books, 20 book chapters, 40 published abstracts, and 200 invited presentations. Dr. Cutler has served on the organizing committees of 22 national and international scientific meetings. He has received 10 teaching awards and recognitions. Past members of Dr. Cutler's research group are employed in various pharmaceutical companies, the NIH, the CDC, the FDA, and the USDA.